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The relationship between hypoalbuminaemia, tumour volume and C-reactive protein was examined in patients with colorectal liver
metastases (n¼57). On multiple regression analysis, albumin concentrations were independently associated with C-reactive protein
(r¼0.56, Po0.001) but not percentage hepatic replacement (P¼0.34). These results show that hypoalbuminaemia is associated
with the presence of a systemic inflammatory response rather than tumour volume in patients with colorectal liver metastases.
British Journal of Cancer (2004) 91, 205–207. doi:10.1038/sj.bjc.6601886 www.bjcancer.com
Published online 22 June 2004
& 2004 Cancer Research UK
Keywords: colorectal liver metastases; hypoalbuminaemia; tumour volume; C-reactive protein; liver enzymes
                            
It has long been recognised that, in patients with advanced cancer,
the presence of hypoalbuminaemia is associated with poor
outcome (Franch-Arcas, 2001). In the past, this hypoalbuminaemia
has been thought to be the result of nutritional depletion
secondary to the tumour. Recently, however, it has been postulated
that the reduction in albumin concentration is secondary to the
presence of a systemic inflammatory response, as evidenced by
elevated circulating concentrations of C-reactive protein (McMil-
lan et al, 2001).
The nature of the relationship between circulating albumin
concentration, tumour burden and the systemic inflammatory
response has not been established. However, if the presence of a
systemic inflammatory response rather than tumour burden were
to determine the development of the hypoalbuminaemia associated
with advanced cancer, then it might be expected that there would
be a stronger relationship between the presence of hypoalbumi-
naemia and the systemic inflammatory response compared with
that between hypoalbuminaemia and tumour volume.
The aim of the present study was to examine the relationship
between circulating albumin concentration, the tumour burden
and the systemic inflammatory response in patients with colorectal
liver metastases.
MATERIAL AND METHODS
Patients
Patients who had undergone resection of a primary colorectal
cancer, who then developed liver metastases and who were referred
for assessment for liver resection, were considered eligible for
study. As part of their assessment, patients underwent dual phase
spiral-computed tomography of the liver. In addition a blood
sample was taken for measurement of routine liver enzymes,
albumin and C-reactive protein. Only those patients who had no
evidence of extrahepatic disease were included in the study. None
of the patients had recent chemotherapy.
The study was approved by the Research Ethics Committee of
Glasgow Royal Infirmary.
Biochemical profile
Albumin, C-reactive protein, alkaline phosphatase, aspartate
transaminase, alanine transaminase and bilirubin concentrations
were assayed using standard methods. Intra- and inter-assay
coefficients of variation were better than 5 and 10% respectively.
Tumour volume and PHR
Tumour volume and percentage hepatic replacement (PHR) were
measured using a similar approach to that previously described
(Purkiss and Williams, 1992; Dworkin et al, 1995). Contrast
enhanced CT-scans were performed using a Somatom plus 4
spiral-CT scanner (Siemens AG, Erlangen, Germany).
The cross-sectional areas of all the metastatic lesions in each
5mm slice were measured by mapping the perimeter of the region
of interest. The total tumour volume was calculated as the sum of
the tumour areas in all slices multiplied by the slice thickness. The
total liver volume was measured in a similar manner, the PHR
calculated as the ratio of tumour to total liver volume multiplied
by 100.
To assess the reproducibility of the method used, two observers
independently measured tumour and liver volumes and PHR in 10
randomly selected patients from the above cohort. The intra-class
correlation coefficients were 0.97 or greater for all comparisons.
To assess the accuracy of the CT-derived measurements of
tumour volume, the CT measurements of tumour volume were
compared with the weight of freshly resected tumour in a separate
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lcohort of nine patients undergoing liver resection. The correlation
coefficient between the CT-derived measurements of tumour
volume and the weight of the resected tumour was greater than
0.99 (Po0.001).
Statistics
The relationships between albumin, PHR and C-reactive
protein were analysed using Pearson correlation coefficients and
multiple linear regression analysis with albumin as the dependent
variable. PHR and C-reactive protein concentration were logarith-
mically transformed to normalise their distributions. The appro-
priateness of the regression model was confirmed by examining
residuals graphically. Associations involving liver enzymes and
bilirubin were analysed using Spearman’s rank correlation
coefficient. Comparisons between groups of patients were carried
out Fisher’s exact test or the Mann-Whitney U-test as appropriate.
SPSS for Windows (SPSS Inc., Chicago, IL, USA) was used for
analysis.
RESULTS
The characteristics of the patients studied are shown in Table 1.
The majority were male, were over the age of 60 years, and had
multiple liver metastases, a PHR less than 25%, an albumin
concentration in the normal range and an elevated C-reactive
protein concentration. Patients with hypoalbuminaemia had
significantly higher concentrations of bilirubin (P¼0.034) and
C-reactive protein (P¼0.006).
There were significant correlations between albumin and PHR
(r¼ 0.34, P¼0.010), albumin and C-reactive protein (r¼ 0.56,
Po0.001) and PHR and C-reactive protein (r¼0.43, P¼0.001). A
multiple regression model combining PHR and C-reactive protein
as predictor variables (r¼ 0.57, Po0.001) did not significantly
improve on a model based on C-reactive protein alone (Table 2).
In the combined model, C-reactive protein was a significant
independent predictor of albumin concentration adjusted for PHR
(Po0.001), while the relationship between albumin and PHR
adjusted for C-reactive protein was not significant (P¼0.34). The
relationship between circulating concentrations of albumin and C-
reactive protein is shown in Figure 1.
There were significant rank correlations between PHR and
alkaline phosphatase (rs¼0.61, Po0.001), aspartate transaminase
(rs¼0.48, P¼0.001), alanine transaminase (rs¼0.32, P¼0.025)
and bilirubin (rs¼0.44, P¼0.002). Of these liver enzymes and
bilirubin, only aspartate transaminase was significantly associated
with C-reactive protein (rs¼0.29, P¼0.045) and albumin
(rs¼ 0.34, P¼0.016).
DISCUSSION
It has been recognised for some time that the degree of
biochemical upset in patients with advanced cancer depends not
Table 1 Characteristics and biochemical parameters of patients with colorectal liver metastases in the presence and absence of hypoalbuminaemia
All patients (n¼57) Albumin X35gl
 1 (n¼36) Albumin o35gl
 1 (n¼21) P-value*
Age (years) 66 (46–88) 66 (46–83) 69 (46–88) 0.408
Sex male/female 38/19 25/11 13/8 0.560
Liver metastases
Single/multiple 14/43 11/25 3/18 0.169
Unilobar/bilobar 32/25 24/12 8/13 0.068
Tumour volume (cm
3) 126 (3–2006) 78 (3–1816) 248 (10–2006) 0.175
PHR (%) 7 (o1–58) 4 (o1–46) 15 (o1–58) 0.186
Biochemistry
Albumin (gl
 1) 37 (18–48) 40 (35–48) 31 (18–34)
Alkaline phosphatase (Ul
 1) 253 (83–1750) 255 (115–1750) 250 (83–1530) 0.810
Aspartate transaminase (Ul
 1) 29 (13–770) 25 (14–72) 48 (13–770) 0.055
Alanine transaminase (Ul
 1) 19 (9–380) 16 (10–110) 31 (9–380) 0.090
Bilirubin (mmoll
 1) 14 (7–240) 13 (7–22) 17 (7–240) 0.034
C-reactive protein (mgl
 1)3 8 ( o6–247) 29 (o6–161) 82 (6–247) 0.006
Median (range), *comparison of groups with albumin X35gl
 1 and albumin o35gl
 1.
Table 2 Analysis of variance for regression of albumin on C-reactive
protein (CRP) and percentage hepatic replacement by tumour (PHR)
Source of
variation
Degrees of
freedom
Sum of
squares
Mean
square F P-value
Total 56 2146.035
Regression 2 707.824 353.912 13.288 o0.001
CRP alone 1 683.266 683.266 25.691 o0.001
PHR adjusted for CRP 1 24.558 24.558 0.922 0.34
PHR alone 1 245.799 245.799 7.114 0.01
CRP adjusted for PHR 1 462.025 462.025 17.347 o0.001
Residual 54 1438.212 26.634
Figure 1 The relationship between albumin and C-reactive protein
concentrations in patients with colorectal liver metastases (n¼57).
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In advanced colorectal cancer where the tumour is disseminated
only to the liver, tumour size is readily assessed by computed
tomography and therefore provides a model in which to
examine the relationship between hypoalbuminaemia and tumour
volume.
It is well recognised that albumin concentration is a stage
independent prognostic factor in patients with advanced colorectal
cancer (O’Gorman et al, 2000; Dixon et al, 2003). In the present
study, there was only a weak relationship between albumin
concentrations and tumour volume, and therefore the prognostic
value of hypoalbuminaemia would not appear to be primarily
dependent on tumour burden.
In contrast, albumin was strongly associated with the magnitude
of the systemic inflammatory response as evidenced by circulating
concentrations of C-reactive protein. Furthermore, in a model
combining albumin, C-reactive protein and PHR, there was no
relationship between albumin and PHR when adjusted for the
effect of C-reactive protein. Therefore, the results of the present
study are consistent with the concept that the systemic inflamma-
tory response is a major determinant of albumin concentrations in
patients with advanced colorectal cancer.
It may be that the presence of a chronic systemic inflammatory
response, with its increased demand for specific amino acids for
acute phase protein synthesis, promotes the degradation of
available body protein including albumin (Preston et al, 1998;
McMillan et al, 2001). Indeed, this relationship between nutritional
decline, albumin concentrations and the systemic inflammatory
response has recently been exploited to form a new prognostic
score in patients with advanced non-small-cell lung cancer
(Forrest et al, 2003).
The results of the present study also showed that increased
activity of the enzymes alkaline phosphatase, aspartate transami-
nase and alanine transaminase reflect increased tumour burden. In
particular, raised alkaline phosphatase activity, a recognised
prognostic factor, was significantly correlated with tumour volume
and therefore its prognostic value would appear to be related to the
size of the liver metastases. These increased enzyme activities are
consistent with previous work in patients with colorectal liver
metastastases (Rougier et al, 1995)
In summary, the results of the present study suggest that, in
patients with advanced colorectal cancer, hypoalbuminaemia is
secondary to the presence of a systemic inflammatory response
rather than nutritional depletion by the tumour.
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